AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06348719 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pain assessment
Description: Pain assessment at day 1 , Day 3,Day 7,Day14,Day 21 , Month 3
Study NCT06348719 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain assessment
Description: Pain assessment at day 1 , Day 3,Day 7,Day14,Day 21 , Month 3
Study NCT06348719 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pain assessment
Description: Pain assessment at day 1 , Day 3,Day 7,Day14,Day 21 , Month 3
Study NCT06348719 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Collect of data on non-reimbursed transport
Description: Collect of data on non-reimbursed transport at Day 3,Day 7,Day14,Day 21 , day 42, Month 3, month 6
Study NCT06348719 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collect of data on non-reimbursed transport
Description: Collect of data on non-reimbursed transport at Day 3,Day 7,Day14,Day 21 , day 42, Month 3, month 6
Study NCT06348719 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Collect of data on non-reimbursed transport
Description: Collect of data on non-reimbursed transport at Day 3,Day 7,Day14,Day 21 , day 42, Month 3, month 6
Study NCT06348719 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Collect of everyday help
Description: Collect of everyday help at inclusion, Day 3,Day 7,Day14,Day 21 , day 42, Month 3, month 6
Study NCT06348719 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collect of everyday help
Description: Collect of everyday help at inclusion, Day 3,Day 7,Day14,Day 21 , day 42, Month 3, month 6
Study NCT06348719 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Collect of everyday help
Description: Collect of everyday help at inclusion, Day 3,Day 7,Day14,Day 21 , day 42, Month 3, month 6
Study NCT06348719 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Collection of the business resumption date
Description: Collection of the business resumption date at Day 3,Day 7,Day14,Day 21 , day 42, Month 3, month 6
Study NCT06348719 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collection of the business resumption date
Description: Collection of the business resumption date at Day 3,Day 7,Day14,Day 21 , day 42, Month 3, month 6
Study NCT06348719 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Collection of the business resumption date
Description: Collection of the business resumption date at Day 3,Day 7,Day14,Day 21 , day 42, Month 3, month 6
Study NCT06348719 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: SF36 questionnaire
Description: SF36 questionnaire at inclusion, Day 3,Day 7,Day14,Day 21 , day 42, month 6
Study NCT06348719 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SF36 questionnaire
Description: SF36 questionnaire at inclusion, Day 3,Day 7,Day14,Day 21 , day 42, month 6
Study NCT05064345 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HB0034
Description: Recombinant Humanized Anti-IL-36R Monoclonal antibody
Study NCT04560309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-alanyl-L-glutamine dipeptide
Description: Intravenous infusion of 0.5 mg/kgbw L-alanyl-L-glutamine dipeptide diluted in normal saline to volume of 500 mL, started after induction of anesthesia for 24 hours.
Study NCT04560309 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusion of 500 mL normal saline, started after induction of anesthesia for 24 hours.
Study NCT06348719 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SF36 questionnaire
Description: SF36 questionnaire at inclusion, Day 3,Day 7,Day14,Day 21 , day 42, month 6
Study NCT06348719 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire EQ5D-5L
Description: Questionnaire EQ5D-5L at day 1, Day 3,Day 7,Day14,Day 21 , day 42, month 3, month 6
Study NCT06348719 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire EQ5D-5L
Description: Questionnaire EQ5D-5L at day 1, Day 3,Day 7,Day14,Day 21 , day 42, month 3, month 6
Study NCT06348719 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire EQ5D-5L
Description: Questionnaire EQ5D-5L at day 1, Day 3,Day 7,Day14,Day 21 , day 42, month 3, month 6
Study NCT06348719 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: FIGO Stadium
Description: FIGO Stadium at inclusion and Day 42
Study NCT06348719 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FIGO Stadium
Description: FIGO Stadium at inclusion and Day 42
Study NCT06348719 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FIGO Stadium
Description: FIGO Stadium at inclusion and Day 42
Study NCT06348719 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Collection of treatments (analgesics and anticoagulants up to J42, complication-related treatments, etc.)
Description: Collection of treatments (analgesics and anticoagulants up to J42, complication-related treatments, etc.) at day 1, Day 3,Day 7,Day14,Day 21 , day 42, month 3, month 6
Study NCT06348719 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collection of treatments (analgesics and anticoagulants up to J42, complication-related treatments, etc.)
Description: Collection of treatments (analgesics and anticoagulants up to J42, complication-related treatments, etc.) at day 1, Day 3,Day 7,Day14,Day 21 , day 42, month 3, month 6
Study NCT06348719 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Collection of treatments (analgesics and anticoagulants up to J42, complication-related treatments, etc.)
Description: Collection of treatments (analgesics and anticoagulants up to J42, complication-related treatments, etc.) at day 1, Day 3,Day 7,Day14,Day 21 , day 42, month 3, month 6
Study NCT06348719 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Collection of adjuvant treatments
Description: Collection of adjuvant treatments at month 6
Study NCT05650307 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: The magnetic field exposure for MRI in this study is similar to standard clinical MR procedures. The powers of all radio frequency fields in this study are at or under FDA guidelines. The CMR techniques performed here have been used in the literature and in our own clinical cardiac MRI service extensively for several years and have an excellent safety profile in our institution.
Study NCT06348719 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collection of adjuvant treatments
Description: Collection of adjuvant treatments at month 6
Study NCT06348719 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Collection of adjuvant treatments
Description: Collection of adjuvant treatments at month 6
Study NCT06348719 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Recording of any complications, emergency room visits/unscheduled consultations, additional work stoppages to the initial one
Description: Recording of any complications, emergency room visits/unscheduled consultations, additional work stoppages to the initial one at Day 3,Day 7,Day14,Day 21 , day 42, month 3, month 6
Study NCT06348719 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Recording of any complications, emergency room visits/unscheduled consultations, additional work stoppages to the initial one
Description: Recording of any complications, emergency room visits/unscheduled consultations, additional work stoppages to the initial one at Day 3,Day 7,Day14,Day 21 , day 42, month 3, month 6
Study NCT06348719 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Recording of any complications, emergency room visits/unscheduled consultations, additional work stoppages to the initial one
Description: Recording of any complications, emergency room visits/unscheduled consultations, additional work stoppages to the initial one at Day 3,Day 7,Day14,Day 21 , day 42, month 3, month 6
Study NCT04842435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COVID-globulin
Description: In a Stage 1 study, COVID globulin is administered to clinical study subjects randomized to groups 1, 2, or 3 by intravenous drip in one of three doses of 1 mL/kg, 2 mL/kg, or 4 mL/kg The initial drug administration rate is from 0.01 mL/kg to 0.02 mL/kg of body weight per minute for 30 minutes. If the drug is well tolerated, the rate of administration can be gradually increased to a maximum of 0.12 mL/kg of body weight per minute. In order to control the drug administration rate, infusion shall be performed with an infusion pump.~In a Stage 2 study, COVID globulin is administered to clinical study subjects randomized to group 1 by intravenous drip at a dose found optimal based on the results of Stage 1 study.
Study NCT04842435 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: COVID-globulin
Description: In a Stage 1 study, COVID globulin is administered to clinical study subjects randomized to groups 1, 2, or 3 by intravenous drip in one of three doses of 1 mL/kg, 2 mL/kg, or 4 mL/kg The initial drug administration rate is from 0.01 mL/kg to 0.02 mL/kg of body weight per minute for 30 minutes. If the drug is well tolerated, the rate of administration can be gradually increased to a maximum of 0.12 mL/kg of body weight per minute. In order to control the drug administration rate, infusion shall be performed with an infusion pump.~In a Stage 2 study, COVID globulin is administered to clinical study subjects randomized to group 1 by intravenous drip at a dose found optimal based on the results of Stage 1 study.
Study NCT04842435 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In a Stage 1 study, Placebo is administered to clinical study subjects randomized to groups 4 by intravenous drip at a dose of 1 mL/kg.~The initial drug administration rate is from 0.01 mL/kg to 0.02 mL/kg of body weight per minute for 30 minutes. If the drug is well tolerated, the rate of administration can be gradually increased to a maximum of 0.12 mL/kg of body weight per minute. In order to control the drug administration rate, infusion shall be performed with an infusion pump.~In a Stage 2 study, placebo is administered to clinical study subjects randomized to group 2 by intravenous drip at a dose equal to the study drug dose.
Study NCT06348719 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Collection of data
Description: Collection of data on age, baseline, BMI, histological type of cancer and surgical approach used
Study NCT06014983 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous fumarate
Description: Participants will supplement with 24 mg elemental iron in the form of ferrous fumarate daily for a minimum of 12 weeks.
Study NCT06014983 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ferrous bisglycinate
Description: Participants will supplement with 24 mg elemental iron in the form of ferrous bisglycinate daily for a minimum of 12 weeks.
Study NCT04566666 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo of SCD-044 product
Study NCT06571968 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: fully guided stent
Description: The guides were designed with metal sleeves for guided drilling and guided implant placement and additional guide sleeves for the stabilization of the template by fixation screws. All surgical procedures with drills were done thiough the stent.
Study NCT06019728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGALSIDASE BETA (GZ419828)
Description: Pharmaceutical form: Lyophilized powder for reconstitution Route of administration: IV infusion
Study NCT06019728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Tablet or solution; Oral
Study NCT06019728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Tablet or solution; Oral
Study NCT06019728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Tablet or solution; Oral
Study NCT06019728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: Tablet or chewable tablet or oral granules; Oral
Study NCT04566666 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SCD-044_Dose 1
Description: SCD-044 tablets in Dose 1.
Study NCT04566666 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SCD-044_Dose 2
Description: SCD-044 tablets in Dose 2
Study NCT04566666 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SCD-044_Dose 3
Description: SCD-044 in Dose 3
Study NCT05142189 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT116
Description: intravenous injection
Study NCT06133712 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Patients will receive injection of 1 microgram/kg dexmedetomidine average (70-100-microgram) (0.7-1ml) plus 4ml lidocaine injection nearby median nerve.
Study NCT06133712 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ozone
Description: Participants will receive a single local injection of 4 ml ozone (10 micrograms/dl) plus to 1 ml lidocaine (1%) using a 25 G needle.
Study NCT06133712 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Patients will receive a single local injection of 5 mL (3 mL lidocaine (1%) and 2 mL \[8 mg\] dexamethasone) via the same technique.
Study NCT05019521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan
Description: Oral tablet.
Study NCT05064345 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Palcebo
Study NCT05575804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GQ1001+pyrotinib
Description: GQ1001 infusions on day 1 of each 21-day cycle combinate with pyrotinib 320mg orally once daily until disease progression or unacceptable toxicity. I.
Study NCT05575804 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pyrotinib+capecitabine
Description: pyrotinib 400mg orally once daily in combination with capecitabine 1000mg/m2 twice daily, day1-14, every three weeks until disease progression or unacceptable toxicity.
Study NCT05477238 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: walking tasks
Description: The experiment will be divided in two sessions. In the first session, the participant/healthy volunteers will do 3 walking tasks (over ground walking/ climbing up, down stairs). In the second session, the participant will walk outside in front of the hospital (walking on a slope, walking down, walking on uneven ground). All those tasks will be done while wearing a gas exchange analyzer, accelerometer and a heart rate meter.
Study NCT05477238 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: walking tasks
Description: The experiment will be divided in two sessions. In the first session, the participant/healthy volunteers will do 3 walking tasks (over ground walking/ climbing up, down stairs). In the second session, the participant will walk outside in front of the hospital (walking on a slope, walking down, walking on uneven ground). All those tasks will be done while wearing a gas exchange analyzer, accelerometer and a heart rate meter.
Study NCT05534334 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solu-Cortef
Description: A vial sol. used for intra-mascular injection
Study NCT05534334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solu-Cortef
Description: A vial sol. used for intra-mascular injection
Study NCT05019521 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Danicopan
Description: Oral tablet.
Study NCT05019521 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet.
Study NCT06059118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFMO
Description: Each 119 day cycle, Days 1-7 patient will take 1000 mg by mouth (PO) twice a day (bid), and then on Day 8 - 63 patient will take 1000 mg PO bid while receiving high dose testosterone IM on Day 8 and Day 36 of cycle.
Study NCT06059118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: testosterone cypionate
Description: On Day 8 and Day 36 of each 119 day cycle, patient will receive high dose testosterone at 400 mg through intramuscular (IM) injection.
Study NCT06059118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luteinizing hormone-releasing hormone (LHRH) analogue
Description: Patients who have progressive disease after treatment with Abiraterone (Abi) will continue with androgen depravation therapy (ADT) with LHRH analogue (LHRH agonist drug (i.e. Zoladex, Trelstar, Eligard or Lupron) or LHRH antagonist drug (Degarelix or Relugolix)). Dosing instructions will vary between the different LHRH analogues. Patients should follow the dosing instructions as directed by their physician.
Study NCT06059118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Each 119 day cycle, Days 64-119 patient will take 160 mg by mouth (PO) once a day (qd).
Study NCT05878561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fimasartan + Indapamide
Description: a fixed dose combination
Study NCT05878561 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fimasartan + Indapamide placebo
Description: a fixed dose combination
Study NCT06571409 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coriander Seed Oil - Dose 1
Description: The study foresees the intake of 1 capsule per day during 56 days
Study NCT06571409 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coriander Seed Oil - Dose 2
Description: The study foresees the intake of 1 capsule per day during 56 days
Study NCT06571409 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The study foresees the intake of 1 capsule per day during 56 days
Study NCT05827263 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: T-Scan occlusal recording No. I
Description: Occlusal information was obtained using the T-Scan device before the main intervention. This process was repeated three times to confirm the findings.
Study NCT05827263 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: T-Scan occlusal recording No. I
Description: Occlusal information was obtained using the T-Scan device before the main intervention. This process was repeated three times to confirm the findings.
Study NCT05827263 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Usage of the hydrostatic appliance
Description: The hydrostatic appliance was removed from its packaging and placed symmetrically between the upper lip and the oral vestibule of the maxilla for the most comfortable position. After 30 minutes, the hydrostatic appliance was removed, and patients were asked to keep their mouths open until the T-Scan was positioned correctly.
Study NCT05827263 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Usage of the hydrostatic appliance
Description: The hydrostatic appliance was removed from its packaging and placed symmetrically between the upper lip and the oral vestibule of the maxilla for the most comfortable position. After 30 minutes, the hydrostatic appliance was removed, and patients were asked to keep their mouths open until the T-Scan was positioned correctly.
Study NCT05827263 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: T-Scan occlusal recording No. II
Description: The occlusal registration was repeated three times using the T-Scan device in order to confirm the findings.
Study NCT05827263 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: T-Scan occlusal recording No. II
Description: The occlusal registration was repeated three times using the T-Scan device in order to confirm the findings.
Study NCT04863131 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EXG-5003
Description: COVID-19 self-replicating mRNA vaccine
Study NCT04863131 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo solution
Study NCT04484740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gepotidacin
Description: Single oral dose of 1500 mg gepotidacin
Study NCT06405815 — intervention group
Intervention type: OTHER
Intervention: tumor and peritumor radiomic feature
Description: extracted the tumor and peritumor radiomic feature from the preoperative enhanced chest CT
Study NCT05214027 — intervention group
Intervention type: OTHER
Intervention: Treadmill-Based Exercise (60% VO2 Max for 60 minutes)
Description: Each participant will undergo a single 60-minute treadmill-based exercise intervention in a randomised order.~Treadmill settings are generated based on settings which correspond to participants exercising at 60% VO2 max from their maximal exercise test on visit 2. To confirm that participants are exercising at 60% during the hour session, 1 minute samples of expired air are taken at 15 minute intervals and immediately analysed to check % VO2 max. Participants heart rate and RPE measures are also taken at 15 minute intervals throughout the exercise session and cross-checked against predicted values at 60% VO2 Max.
Study NCT05214027 — intervention group
Intervention type: OTHER
Intervention: Rest (60 minutes)
Description: Each participant will undergo a 60-minute rest period in a randomised order.
Study NCT05675293 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IONTOPHORESIS
Description: The process of increasing the penetration of drugs into the skin by application of an electric current
Study NCT04475315 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Papillary Muscle Sling
Description: The sling is made of a Gore-Tex sheet or by using a 4 mm Gore-Tex vascular graft implanted around the base of the papillary muscles and tightened.